BioPartners licenses sustained release hGH from Korea's LG Chem

1 November 2001

BioPartners and LG Chemical Industries have entered into an agreementfor the commercialization of a slow-release recombinant human growth hormone which is currently in Phase II clinical trials. Early data indicate that this formulation is as effective as current hGH formulations, but with a more convenient dosing schedule. Under the terms of the agreement, BioPartners gains marketing and distribution rights for the drug in key territories, including Europe, Japan, Australia, New Zealand and the Middle East.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight